American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal definition of myocardial infarction classification system and the risk of cardiovascular death: Observations from the TRITON-TIMI 38 trial

Circulation

Volumn 125, Issue 4, 2012, Pages 577-583

  Bonaca, Marc P ^a   Wiviott, Stephen D ^a   Braunwald, Eugene ^a   Murphy, Sabina A ^a   Ruff, Christian T ^a   Antman, Elliott M ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

mortality; myocardial infarction; outcomes

Indexed keywords

PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOLOGY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; AMERICAN HEART ASSOCIATION; BLOOD PLATELETS; DEATH, SUDDEN, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIOPHENES; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 84857098194     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.041160     Document Type: Article

References (24)

1. Thygesen K, Alpert JS, White HD; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007;116: 2634-2653. (Pubitemid 350182388)
2. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008;372: 570-584.
3. Alpert JS, Thygesen K, White HD, Jaffe AS. Implications of the universal definition of myocardial infarction. Nat Clin Pract Cardiovasc Med. 2008;5:678-679.
4. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol. 2007;128:282-286. (Pubitemid 47262627)
5. Melanson SE, Conrad MJ, Mosammaparast N, Jarolim P. Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. Clin Chim Acta. 2008;395:57-61.
6. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, Rubartelli P, Battaglia S, Niccoli L, Steffenino G, Ardissino D; Italian "Atherosclerosis, Thrombosis, and Vascular Biology" and "Society for Invasive Cardiology-GISE" Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-1498. (Pubitemid 41373489)
7. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J. 2006;27:1061-1069.
8. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
9. Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM; TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J. 2009;158: e21-e26.
10. Van de Werf F. Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome. Circulation. 2010;121:5-7.
11. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2010;121:43-51.
12. Unger EF. Weighing benefits and risks: the FDA's review of prasugrel. N Engl J Med. 2009;361:942-945.
13. Kastrati A, Ndrepepa G. Cangrelor: a champion lost in translation? N Engl J Med. 2009;361:2382-2384.
14. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009;119:2758-2764.
15. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152: 627-635. (Pubitemid 44396884)
16. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842. (Pubitemid 30643610)
17. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858-867.
18. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, Van de Werf F, Lee KL, Califf RM; GUSTO-IIb Investigators. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation. 1998;98:1860-1868. (Pubitemid 28509281)
19. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536. (Pubitemid 26320254)
20. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalan R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA; PURSUIT Steering Committee. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA. 2000;283:347-353. (Pubitemid 30051752)
21. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406-1411. (Pubitemid 37267281)
22. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23: 869-876. (Pubitemid 34717422)
23. Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, Sharma SK. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18-23. (Pubitemid 38022028)
24. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522-528. (Pubitemid 36390500)